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Spatial distribution of B cells and lymphocyte clusters as a
predictor of triple-negative breast cancer outcome
Juliana C. Wortman1,8, Ting-Fang He 2,8, Shawn Solomon 2, Robert Z. Zhang2, Anthony Rosario2, Roger Wang 2, Travis Y. Tu 2,
Daniel Schmolze 3, Yuan Yuan4, Susan E. Yost 4, Xuefei Li5, Herbert Levine 5,6, Gurinder Atwal7, Peter P. Lee 2,9✉ and
Clare C. Yu 1,9✉
While tumor infiltration by CD8+ T cells is now widely accepted to predict outcomes, the clinical significance of intratumoral B cells is
less clear. We hypothesized that spatial distribution rather than density of B cells within tumors may provide prognostic significance.
We developed statistical techniques (fractal dimension differences and a box-counting method ‘occupancy’) to analyze the spatial
distribution of tumor-infiltrating lymphocytes (TILs) in human triple-negative breast cancer (TNBC). Our results indicate that B cells in
good outcome tumors (no recurrence within 5 years) are spatially dispersed, while B cells in poor outcome tumors (recurrence within
3 years) are more confined. While most TILs are located within the stroma, increased numbers of spatially dispersed lymphocytes
within cancer cell islands are associated with a good prognosis. B cells and T cells often form lymphocyte clusters (LCs) identified via
density-based clustering. LCs consist either of T cells only or heterotypic mixtures of B and T cells. Pure B cell LCs were negligible in
number. Compared to tertiary lymphoid structures (TLS), LCs have fewer lymphocytes at lower densities. Both types of LCs are more
abundant and more spatially dispersed in good outcomes compared to poor outcome tumors. Heterotypic LCs in good outcome
tumors are smaller and more numerous compared to poor outcome. Heterotypic LCs are also closer to cancer islands in a good
outcome, with LC size decreasing as they get closer to cancer cell islands. These results illuminate the significance of the spatial
distribution of B cells and LCs within tumors.
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INTRODUCTION
The evolution and progression of cancer is dependent on the
tumor microenvironment (TME), which consists of cancer cells,
collagen fibers, blood vessels, lymph vessels, fibroblasts, and
various types of immune cells. High densities of tumor-infiltrating
lymphocytes (TILs) correlate with favorable clinical outcomes in
different types of cancer1–3, including triple-negative and HER2-
positive breast cancers4. While the prognostic value of the density
of CD3+ and CD8+ T cells infiltrating tumors is well known, e.g.,
recurrence in colorectal carcinoma5, the clinical significance of B
cell density in tumors is less clear6,7. Recent studies indicate that B
cells in tumors, especially in conjunction with organized lymphoid
aggregates known as tertiary lymphoid structures (TLS), are
significant predictors of response to immunotherapy, i.e., immune
checkpoint blockade, in melanoma8,9, soft tissue sarcomas10, and
renal cell carcinoma9. However, the possible clinical relevance of
non-TLS B cells in tumors should not be overlooked as B cells can
perform a variety of functions, including antibody production,
cytokine secretion, and antigen presentation to helper T cells.
We hypothesized that the spatial patterns of B cells within
tumors may be more informative than density alone. Focusing on
cell densities averaged over the entire tissue overlooks the
possible significance of spatial heterogeneity of TILs11–13. Further-
more, spatial heterogeneity could skew the density measured in
tissue microarrays (TMA), which only account for a small region
within each tumor—such samples may give a poor estimate of the
overall cell density, depending on the location of each TMA
sample within the tissue. In addition, the TME is spatially
heterogeneous with aggregates of cancer cells (cancer cell islands)
interspersed with stroma (Fig. 1a, b). In this paper, we utilized
density-based clustering algorithm, occupancy, and fractal dimen-
sion (FD) approaches to investigate the clinical relevance of the
spatial distribution of B and T cells as well as lymphocyte clusters
(LCs) in triple-negative breast cancer (TNBC) tumors.
RESULTS
Patient cohort and tissue sample preparation
We examined immunohistochemistry (IHC)-based images of
primary TNBC tumors (Fig. 1a, b) from 36 patients prior to
treatment. Patients with no recurrence within 5 years after surgery
were defined as good clinical outcome (n= 24) and patients who
had recurrence within 3 years after surgery as poor clinical
outcome (n= 12). All patients received standard of care treat-
ments, which included chemotherapy and also radiotherapy in
some. None received treatment prior to tumor resection. (See
Table 1 for patient clinicopathological characteristics.) Normal
breast tissues from nine patients who underwent breast reduction
surgery (age 18–45) served as controls.
Formalin-fixed paraffin-embedded (FFPE) tumor tissues
were sectioned (i.e., 3–5 μm per slide) and baked onto glass
microscope slides. The following cell phenotypes were identified
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on the same slide: T cells (CD3+), B cells (CD20+), epithelial/cancer
cells (PanCK), or “other” (n= 36). Cells were counterstained with
DAPI to show the locations of nuclei. In an adjacent slide, a subset
of this cohort (27 patients: n= 19 good, n= 8 poor) was co-
stained for CD20+ B cells, CD8+ cytotoxic T cells, CD4+Foxp3+
regulatory T cells (Tregs), and CD4+Foxp3− helper T cells (Th). In
this cohort, we will regard CD8+ cytotoxic T cells, CD4+Foxp3+
regulatory T cells, and CD4+Foxp3− helper T cells collectively as
CD3+ T cells. A pathologist delineated tumor regions that were
deemed representative of the entire tumor in terms of cellularity
and TIL distribution, and that were free of artifacts such as tissue
folding. Areas of necrotic tumor were avoided, as were peri-
tumoral lymphoid aggregates not in close proximity to tumor
cells. Given these constraints, regions were chosen to maximize
tumor area.
The mean and median values for various quantities were
calculated for each patient and then the average of these values
for a given cohort, e.g., good outcome patients, was reported.
Statistical significance was ascertained using the two-sided
Student’s t-test p-value (p < 0.05) to reject the null hypothesis,
and receiver operating characteristic (ROC) area under the curve
(AUC), both standard statistical measures of a binary classifier14.
CD20+ B cell density in entire tumors is not clinically
significant
Consistent with previous studies6,7, mean CD20+ B cell density in
tumors was not significantly different between good and poor
outcome (good (n= 24): 2.4 × 102/mm2; poor (n= 12): 2.2 × 102/
mm2; p= 0.8, ROC AUC= 0.6) (Fig. 1c). Relapse-free survival
(RFS) curves using a B cell density threshold of 55 cells/mm2
(see Methods) were non-significant for clinical outcome patients
(Fig. 1d).
Densities of CD20+ B and CD3+ T cells within cancer cell
islands are significantly higher in good outcome
While the clinical significance of B cell density within the entire
tumor tissue was not significant, this does not preclude the
possible clinical significance of local density of B cells within
distinct locations, i.e., in cancer islands (CI) or stroma. Indeed, the
density of CD20+ B cells in cancer cell islands (defined as the
ratio of the number of B cells in cancer cell islands to the area of
the imaged tissue inside the pathologist’s outline, i.e., the region
of interest (ROI)) was significantly higher in good compared to
poor outcome (good (n= 24): 23 B cells/mm2; poor (n= 12): 1.9 B
cells/mm2; p= 0.002) (Fig. 1e). Clinical significance is shown in
the RFS plot in Fig. 1f. For comparison, we found that the CI
density of CD3+ T cells was also significantly higher in good
outcome (good (n= 24): 29 T cells/mm2; poor (n= 12): 56 T cells/
mm2; p= 0.007) (Fig. 1g). In contrast, the density of CD20+ B cells
in stroma (defined as the ratio of the number of B cells in the
stroma to the area of the ROI), was not clinically significant (good
(n= 24): 33 stromal B cells/mm2; poor (n= 12): 27 stromal B
cells/mm2; p= 0.6).
Fig. 1 Overall CD20+ B cell density is not clinically significant, but the density of TILs within cancer cell islands is significant. a Sample
image of TNBC tissue illustrating the heterogeneity of the tumor microenvironment. Color code: T cells (CD3+; green), B cells (CD20+; cyan),
cytotoxic T cells (CD8+; bright red), regulatory T cells (FoxP3+, magenta), cancer cells (Pan-cytokeratin cells; dark brownish red), and nuclei
(DAPI; dark blue). Cancer cell islands correspond to clusters of cancer cells (dark brownish red). Scale bar= 100 μm. b Example of cancer cell
islands interspersed with stroma. Color code: T cells (CD3+; green), B cells (CD20+; cyan), cancer cells (Pan-cytokeratin cells; red), and nuclei
(DAPI; dark blue). Scale bar= 50 μm. c, d The density of B cells overall in tumor does not differentiate between good vs. poor outcome. c Box
and whisker plot showing CD20+ B cell density in the entire tumor is not significantly different between good (n= 24) vs. poor (n= 12)
outcome. Center line represents the median, box limits represent the upper and lower quartiles, whiskers indicate maximum and minimum
values within 1.5 interquartile ranges of the upper and lower quartiles; individual points are outliers. d Relapse-free survival (RFS) plot showing
that CD20+ B cell density in the entire tumor is not a significant factor in TNBC clinical outcome, using a threshold value of 55 cells/mm2 as
described in “Methods”. e–g Density of B and T cells within cancer cell islands is clinically significant. e Plot showing density of CD20+ B cells
within cancer cell islands is higher for good (n= 24) vs. poor (n= 12) outcome (p= 0.02). Center line represents the median, box limits
represent the upper and lower quartiles, whiskers indicate maximum and minimum values within 1.5 interquartile ranges of the upper and
lower quartiles; individual points are outliers. f RFS plot showing the clinical significance of density of CD20+ B cells within cancer cell islands
using a threshold value of 0.974 cells/mm2 (see “Methods”). g Plot showing density of CD3+ T cells within cancer cell islands is higher for good
(n= 24) vs. poor (n= 12) outcome (p= 0.01). Center line represents the median, box limits represent the upper and lower quartiles, whiskers
indicate maximum and minimum values within 1.5 interquartile ranges of the upper and lower quartiles; individual points are outliers.
h RFS plot showing the clinical significance of density of CD3+ T cells within cancer cell islands using a threshold value of 34.8 cells/mm2
(see “Methods”). P-values in box plots are determined by unpaired, two-tailed Student t-tests. ns: not significant; *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 1 × 10−4.
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B cells in stroma are more spatially dispersed in good clinical
outcome
Although the density of CD20+ B cells in stroma is not clinically
significant, we hypothesized that their spatial patterns may be
informative. We investigated the spatial distribution of CD20+ B
cells by developing two statistical techniques: occupancy and FD
difference15,16. Both techniques are quantitative measures of the
spatial dispersion of cells. We use the terms “spread out”, “spread
apart”, and “spatial dispersion” synonymously to connote both
separations between cells as well as coverage of the tissue or
tissue region in question since lymphocytes are not contiguous
throughout the entire tissue. (For example, confluent cells in vitro
are spread out over an entire region but without any separation
between adjacent cells.)
Using our occupancy analysis (described in “Methods” and Fig.
2a), Fig. 2b is a plot of the average occupancy for CD20+ B cells in
stroma versus square size L for 36 patients. Of interest, B cells are
not randomly Poisson distributed within tumors (black line).
Occupancy of CD20+ B cells in normal breast tissue (gray) is
compared to that of stromal CD20+ B cells within tumors from
good outcome patients (blue) and poor outcome patients (red).
The difference in occupancy between patients with good and
poor clinical outcome reflects, to some extent, the minor
difference in B cell density since a higher density corresponds to
a higher probability that a square will be assigned a ‘1’ in
computing occupancy. The area under the occupancy curve
(occupancy AUC) is correlated with outcome (p= 0.05, ROC AUC
= 0.70) as shown in Fig. 2c. The modestly higher value of
occupancy for good outcome indicates that CD20+ B cells are
more spatially dispersed for good outcome and, in contrast, more
spatially confined for poor outcome.
Fractal dimension (FD)
To introduce FD, the number of tiles, each with area L2, required to
cover the floor of a room is proportional to 1/L2, where the
exponent 2 reflects the two-dimensional floor. Similarly, the
number n(L) of squares with 1’s is proportional to 1/Ld, where d is
one way to define the FD17. Our definition of FD is slightly
different (see “Methods” and Fig. 2d) and allows us to characterize
a range of length scales with a single FD. (“Length scale” refers to
the box size. It can also be roughly thought of as the magnification
factor. Small length scales correspond to large magnification
factor.) Although a number of papers have used FD to analyze
morphologies associated with tumors18–24, here the purpose is to
quantify the spatial distribution of immune cells. Figure 2d shows
a plot of ln(n(L)) versus ln(1/L) for stromal CD20+ B cells. At small
(10–40 μm) and large (200–600 μm) length scales, the slope of
straight lines fitting the data on this log-log plot corresponds to
the FD. Large FD, i.e., close to two, corresponds to a more spatially
uniform and area-filling spatial distribution of cells. FD is larger for
the good clinical outcome than for the poor outcome at large
length scales, but this trend is reversed at small length scales. This
is key to the FD difference described below which demonstrates
that CD20+ B cells are more spatially dispersed. As expected,
randomly placed points (uniform Poisson process) have a FD of
two at length scales large compared to the average separation of
points. Further details are given in the “Methods” section.
FD difference indicates whether cells are spatially dispersed or
aggregated15,16
The spatial dispersion of cells is reflected in the difference Δs in FD
between large and small length scales: Δs= sLarge − ssmall, where
sLarge is the FD at large length scales and ssmall is the FD at small
length scales. The small and large length scales should roughly
bracket the typical, or median, nearest neighbor distance between
cells of the same type, e.g., CD20+ B cells. Since the mean nearest
neighbor distance between B cells is about 60 μm, we determine
ssmall (sLarge) over the range 10–40 (200–600)μm. In all cases
examined, Δs > 0. Large Δs indicates that cells are more dispersed,
i.e., more spatially spread out and separated because they appear
more two-dimensional at large length scales and more zero-
dimensional (point-like) at small length scales. (Fig. 2e explains
why FD difference is a measure of spatial dispersion.) Δs= 0
indicates that FD does not change with length scale, i.e., the
system is self-similar and fractal. Small Δs corresponds to a system
that is closer to being fractal (see Fig. 2e).
FD difference Δs for stromal CD20+ B cells is plotted in Fig. 2f
where we see that Δs is large (Δs= 0.72) for good (n= 24)
outcome, indicating that stromal B cells are spatially spread out,
but small (Δs= 0.46) for poor (n= 12) outcome, indicating that
stromal B cells are spatially confined. Figure 2f shows that FD
difference is clinically significant (p= 3 × 10−3, ROC AUC= 0.77)
(see also the RFS plot in Fig. 2g). For stromal CD20+ B cells, Δs is
not statistically correlated with stromal B cell density (p= 0.4, r=
0.16), indicating that spatial distribution of B cells is an
independent predictor of clinical outcome.
Spatial distribution of clustered lymphocytes vs. isolated
lymphocytes: Identification of LCs with density-based
clustering algorithm (DBSCAN)
Visual examination of tumors revealed that TILs form clusters, LCs,
within the stroma. To quantify LCs and investigate their spatial
distribution, we utilized a common density-based clustering
algorithm (DBSCAN)25. LCs are identified as containing at least
five lymphocytes (T and/or B cells) within a circle with a diameter
of 40 μm, corresponding to the minimum size containing the
centers of five contiguous cells along a line assuming a cell
diameter of 10 μm (Fig. 3a). An example with LCs in a scatter plot






# of Patients 24 12 9
Mean age 55 58 24
Age range 27–76 46–79 18–45
Stage I 5 6
Stage II 17 6










Grade 1 0 0
Grade 2 3 0





In the TNM classification, T denotes tumor size, N denotes lymph node
invasion, and M denotes the metastasis status.
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of lymphocytes is shown in Fig. 3b. LCs consist of T cells only (T
LCs) or mixed T and B cells (heterotypic LCs). B cell only LCs
constituted <1% of all LCs and were very small (<10 lymphocytes/
LC). Figure 3c, d shows heterotypic LCs in sample tissue images
from poor and good outcome patients, respectively. Of note,
Fig. 3c, d illustrate lymphocytes that are spatially dispersed in
good outcome (Fig. 3c) or spatially confined in poor outcome
(Fig. 3d). This is consistent with our occupancy and FD difference
calculations above. Lymphocytes are either within LCs or isolated,
i.e., not part of an LC. Isolated lymphocytes will be considered first.
Fig. 2 Occupancy, fractal dimensions, and FD differences indicate that stromal B cells are more spread out in good outcome.
a–c Occupancy: a Example image showing how occupancy is computed. A grid of squares placed over the image. (Inset) 1’s (0’s) correspond to
yes (no) answers to a binary question asked of each square, e.g., “Is there at least one B cell in the square?” Occupancy is fraction of squares
with 1’s. b Plot of CD20+ B cell occupancy in stroma vs. square size for good clinical outcome (blue), poor clinical outcome (red), normal breast
tissue (black) and points randomly distributed according to a uniform Poisson process with a density of 3 × 102 points/mm2 (cyan). Error bars
indicate 95% confidence intervals. Good (blue) outcome curve is consistently higher than poor (red) outcome curve. c Plots showing
occupancy area under the curve (AUC) for CD20+ B cells in stroma is higher for good (n= 24) vs. poor (n= 12) outcome (p= 0.05). Center line
represents the median, box limits represent the upper and lower quartiles, whiskers indicate maximum and minimum values within 1.5
interquartile ranges of the upper and lower quartiles; individual points are outliers. d Fractal dimension determined from slope of the log-log
plot of the number of squares with at least one stromal CD20+ B cell vs. the inverse box size (Logarithms are base e). The fractal dimension is
larger for good clinical outcome vs. poor outcome at large length scales, but this trend is reversed at small length scales. At long length scales
(200–600 μm on the left side of the plot), mean fractal dimension s (slope) is 1.3 for good outcome (blue), 1.11 for poor outcome (red), 0.92 for
normal tissue (gray), and 2.08 for Poisson (black). The p value for good vs. poor outcome is 0.08 at long length scales. At short length scales
(10–40 μm on the right side of the plot), the mean fractal dimension is 0.58 for good outcome, 0.65 for poor outcome, 0.30 for normal tissue,
and 0.15 for Poisson. The p value for good vs. poor outcome is 0.5 at short length scales. Black dashed lines show least-squares linear
regression fit at long and short length scales. Because different images have different overall areas, fractal dimension is calculated by
normalizing the number n(L) of boxes with 1’s with the total number N(L) of boxes with cells. Thus the y-axis values are negative. The error
bars correspond to 95% confidence intervals. e Example illustrating how FD difference indicates whether cells are spread out or clustered. The
left image with four quadrants shows four blue points that are spatially spread out in the upper two quadrants while the right image with four
quadrants shows four clustered red points in the upper two quadrants. At long length scales (big boxes in left 2 quadrants), the big squares in
the lower left quadrant have more 1 s in the left image than in the lower left quadrant of the right image because the blue points in the upper
left quadrant are more spread out compared to the red points in the upper left quadrant of the right image, so the fractal dimension is larger
in the left half of left image than in the left half of the right image. At small length scales (small boxes in 2 right quadrants), the upper right
quadrants of both images have the same number of points and occupy the same number of squares; hence, the blue and red points have the
same fractal dimension at small length scales. So the difference in fractal dimension between large and small length scales will be larger for
the spatially dispersed blue points than for the clustered red points. f Plot showing that the FD difference for stromal CD20+ B cells is
significantly higher in good outcome (p= 3 × 10−3, ROC AUC= 0.77), indicating that B cells are more spatially dispersed in the stroma in good
outcome. Center line represents the median, box limits represent the upper and lower quartiles, whiskers indicate maximum and minimum
values within 1.5 interquartile ranges of the upper and lower quartiles; individual points are outliers. g RFS plot showing the clinical
significance of the FD difference for stromal CD20+ B cells with a threshold value= 0.564 (see “Methods”). For all FD differences calculated in
this paper, the large length scale range is 200–600 μm and the small length scale range is 10–40 μm. Patient cohorts for all plots in this figure
are n= 24 for good outcome (blue) and n= 12 for poor outcome (red). P-values in box plots are determined by unpaired, two-tailed Student
t-tests. ns: not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 1 × 10−4.
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Density and spatial dispersion of CD20+ B and CD3+ T cells
infiltrating cancer cell islands are higher in the good outcome
than in the poor outcome
The majority of lymphocytes within cancer cell islands are isolated,
i.e., not in LCs (good (n= 24): 0.64; poor (n= 12) 0.76; p= 0.04).
The density of isolated lymphocytes (p= 0.006), as well as isolated
CD20+ B (p= 0.02) and CD3+ T cells (p= 0.007), infiltrating cancer
cell islands is significantly higher in good outcome (n= 24) vs.
poor outcome (n= 12) (Fig. 4a–e). (Density is defined as the ratio
of the number of cells in cancer cell islands and the ROI area.)
Spatial dispersion of isolated CD20+ B and CD3+ T cells within
cancer cell islands, as measured by occupancy AUC (B cells:
p= 0.004; CD3+ T cells: p= 7 × 10−5) and FD difference (B cells:
p= 0.007; CD3+ T cells: p= 0.0003), is significantly larger in good
outcome (Fig. 4f–i).
CD20+ B and CD3+ T cells within cancer islands, regardless of
whether or not they are isolated or clustered, exhibit significantly
greater spatial dispersion in good (n= 24) vs. poor (n= 12)
outcome as indicated by occupancy AUC as well as FD difference
(Fig. 4j–m). Associated RFS plots in Fig. 4n, o show the clinical
significance of CD20+ B cell occupancy AUC and FD difference.
Densities of CD20+ B and CD3+ T cells in cancer cell islands,
without regard to outcome, are significantly correlated (Fig. 4p).
Density and spatial dispersion are higher in good outcome vs.
poor outcome for isolated CD3+ T cells but not isolated CD20+
B cells in the stroma
Only a small fraction of lymphocytes in the stroma are isolated
(good (n= 24): 0.27; poor (n= 12) 0.33; p= 0.4). While the
density of isolated lymphocytes (p= 0.004), as well as isolated
CD3+ T cells (p= 0.002), within stroma is significantly higher in
good outcome (n= 24) vs. poor outcome (n= 12) tumors, the
density of isolated stromal CD20+ B cells is not significant (p=
0.5) for outcome (Fig. 5a–c). (Density is defined as the ratio of
the number of cells in the stroma and the area of ROI.) In
addition, spatial dispersion of isolated CD3+ T cells within the
stroma, as measured by occupancy AUC (p= 0.02) and FD
difference (p= 0.006), is significantly larger in good vs. poor
outcome (Fig. 5d–g). However, spatial dispersion of isolated
stromal CD20+ B cells is not significant (occupancy AUC: p= 0.1;
FD difference: p= 0.3).
LCs consist purely of T cells or heterotypic mixtures of B and
T cells
LCs, which are almost entirely in the stroma, either consist purely
of CD3+ T cells or mixtures of CD3+ T and CD20+ B cells (referred
to as “heterotypic LCs”). Less than 1% of LCs are purely B cells and
these are very small clusters. Fifty-seven percent of LCs are purely
CD3+ T cells while 42% are a mixture of T and B cells with no
significant difference in these percentages between good and
poor outcomes.
TLS are a clinically insignificant subset of LCs in TNBC tumors
TLS consist of densely packed lymphocytes with a T-cell-rich zone
next to a B cell follicle26. While TLS are a subset of LCs, most of the
LCs identified using our clustering algorithm are morphologically
distinct from TLS and not as densely packed. Most LCs have
much fewer lymphocytes at a lower density than TLS. The
neighbors of lymphocytes in TLS are other lymphocytes while the
neighbors of lymphocytes in non-TLS LCs can be a variety of cell
types including fibroblasts, cancer cells, and other lymphocytes.





Fig. 3 Lymphocyte clusters (LCs) within tumors. a Cartoon illustrating density-based clustering algorithm (DBSCAN). LCs contain at least five
lymphocytes within a circle with a diameter of 40 μm. b Figure illustrating LCs identified in a tumor sample from a poor outcome patient. Each
color corresponds to a unique LC. Black points are isolated lymphocytes. c, d Tumor samples with heterotypic LCs (circled) and isolated
lymphocytes from (c) poor outcome and (d) good outcome. Scale bar= 500 μm in (c) and 100 μm in (d). Green line is the pathologist’s outline
of the tumor region. Color code: Nuclei (DAPI, dark blue), T cells (CD3+; green), B cells (CD20+; cyan), cytotoxic T cells (CD8+; yellow),
regulatory T cells (FoxP3+, yellow), and cancer cells (Pan-cytokeratin cells; magenta in (c) and dark brownish red in (d)).
J.C. Wortman et al.
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endothelial venules (PNAd) and for dendritic cells (DC-LAMP)
(good: n= 4, poor: n= 4) also supports that most LCs are not TLS
(data not shown). We defined TLS as containing at least 200
lymphocytes in a circle of radius 70 μm because TLS identified in
this way agree with those we can identify visually by immunos-
taining and with the concept that TLS consist of large groups of
densely packed lymphocytes (Fig. 6a).
Recently, TLS together with B cells are predictive of response to
immune checkpoint blockade (ICB) in metastatic melanoma
tumors8,9 and soft tissue sarcomas10. In TNBC tumors, we do not
observe a significant clinical difference in the fraction of all B cells
belonging to TLS (good (n= 18): 0.24; poor (n= 8): 0.27; p= 0.7),
the fraction of tissue area occupied by TLS (good (n= 18): 0.01;
poor (n= 8): 0.01; p= 0.8), the fraction of all lymphocytes
belonging to TLS (good (n= 18): 0.11; poor (n= 8): 0.14; p=
0.5), nor in the fraction of TLS lymphocytes that are B cells (good
(n= 18): 0.50; poor (n= 8): 0.60; p= 0.2). Furthermore, most B cells
are not in TLS; the majority (about 85%) of B cells are in
(heterotypic) LCs. We investigated LC properties, e.g., composition,
size, spatial distribution, and location relative to cancer islands, to
determine their clinical relevance.
Fig. 4 Density and spatial dispersion of B and T cells infiltrating cancer cell islands are higher in good outcome. a, b Examples of CD20+
B cells (circled) within cancer cell islands in (a) good (scale bar= 100 μm) and (b) poor outcome tumors (scale bar= 200 μm). Color code: T cells
(CD3+; green), B cells (CD20+; cyan), cancer cells (Pan-cytokeratin cells; dark brownish red), and nuclei (DAPI; dark blue). Scale bar= 100 μm
(a), 200 μm (b). c–e Plots showing density of isolated (c) lymphocytes, (d) CD20+ B cells and (e) CD3+ T cells infiltrating cancer cell islands is
higher for good (n= 24) vs. poor (n= 12) outcome tumors. f–g Plots showing occupancy AUC of isolated (f) B cells and (g) CD3+ T cells
infiltrating cancer cell islands is higher for good (n= 24) vs. poor (n= 12) outcome tumors. h–i Plots showing FD difference of isolated (h) B
cells and (i) CD3+ T cells infiltrating cancer cell islands is higher for good (n= 24) vs. poor (n= 12) outcome tumors. j–o B and T cells (including
both isolated and LC lymphocytes) are more spread out within cancer cell islands in the good outcome: Plots showing occupancy AUC of (j)
CD20+ B cells and (k) CD3+ T cells within cancer cell islands is higher in good outcome (B cells: p= 3 × 10−3; T cells: p= 6 × 10−5). Plots
showing FD difference of (l) CD20+ B and (m) CD3+ T cells within cancer cell islands is higher for good vs. poor outcome (B cells: p= 8 × 10−4;
T cells: p= 2 × 10−3). n RFS plots showing the clinical significance of occupancy AUC of CD20+ B cells within cancer cell islands with a
threshold value= 5 corresponding to the fraction of poor outcome patients. o RFS plot showing the clinical significance of FD difference of
CD20+ B cells within cancer cell islands with a threshold value= 0.174 (see “Methods”). p Densities of B and T cells (both isolated and in LCs)
within cancer islands are significantly correlated (Pearson r= 0.45, p= 0.006) even if no distinction is made between good and poor outcome.
For all box-and-whisker plots, the center line represents the median, box limits represent the upper and lower quartiles, whiskers indicate
maximum and minimum values within 1.5 interquartile ranges of the upper and lower quartiles; individual points are outliers. P-values in box
plots are determined by unpaired, two-tailed Student t-tests. ns: not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 1 × 10−4.
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Most B and CD3+ T cells are in heterotypic LCs
The majority of CD20+ B cells (good (n= 24): 0.85; poor (n= 12):
0.84; p= 0.7) and CD3+ T cells (good (n= 24): 0.69; poor (n= 12):
0.78; p= 0.5) within tumors are found within heterotypic LCs. The
fraction of heterotypic LCs with more than 30% B cells is
significantly larger in poor outcome (good (n= 24): 0.25; poor
(n= 12): 0.37; p= 0.02) (Fig. 6b). This is consistent with the mean
relative proportion of B cells in heterotypic LCs being higher in
poor outcome (Table 2). The relative proportions of T cells in LCs
are shown in Table 2. The lower proportion of B cells complements
the higher proportion of CD3+ T cells in good outcome since B
and CD3+ T cell proportions must sum to 1. The higher proportion
of T cells is commensurate with the higher density of CD3+ T cells
in good outcome.
Heterotypic and pure T cell LCs are more abundant in good
outcome patients compared to poor outcome patients
Good outcome patients had a significantly higher number of
heterotypic LCs per unit area compared to poor outcome (good
(n= 24): 960/cm2; poor (n= 12): 520/cm2; p= 0.04) (Fig. 6c).
Similar results hold for pure T cell LCs (good (n= 24): 1420/cm2;
poor (n= 12): 517/cm2; p= 0.005) (Fig. 6d).
Good outcome has smaller, more numerous heterotypic LCs
compared to poor outcome
Distribution of cluster sizes, i.e., number of lymphocytes per
cluster, of heterotypic LCs indicates that good outcome tumors
have a greater number of smaller clusters than poor outcome
tumors (Fig. 6e). Cumulative fraction of lymphocytes that belong
to heterotypic LCs of a given size (population) or smaller shows
that there are more small clusters in good outcome, and more
large clusters in poor outcome, as indicated by crossing of the
curves at large cluster sizes (inset of Fig. 6e). Corresponding plot
for pure T cell LCs lacks the same distinction between good vs.
poor outcome (Fig. 6f). Because the distribution of cluster sizes is
skewed, mean and median cluster sizes were not clinically
significant for heterotypic LCs (mean: p= 0.8, median: p= 0.8),
though for pure T cell LCs, median size was significant (mean: p=
0.6; median: p= 0.01). Mann–Whitney test shows that distribu-
tions of heterotypic and pure T cell LCs are significantly different
(p < 2 × 10−16). However, pure T cell LCs are typically much smaller
than heterotypic LCs.
B cells in heterotypic LCs are more spread out in good
outcome
Spatial dispersion of B (or T) cells in LCs was ascertained using
occupancy AUC and FD difference, which were calculated by
assigning a ‘1’ to squares that had at least one B (or T) cell that was
in a heterotypic LC. Both quantities are significant for B cells
(occupancy AUC: p= 0.02; FD difference: p= 0.008), indicating
that B cells in LCs are more spatially dispersed in good outcome
and more spatially confined in poor outcome, similar to our results
above for B cells (Fig. 6g, h).
It is not a contradiction that B cells in clusters are more spread
out because occupancy and FD difference survey B cells in
heterotypic LCs throughout the tissue. Larger spatial dispersion of
B cells in LCs in good outcome implies that heterotypic LCs are
more spread out and spatially separated compared to poor
outcome, where heterotypic LCs are more spatially confined
(illustrated in Fig. 6i). In good outcome tumors, heterotypic LCs are
smaller and more abundant compared to poor outcome tumors,
which have fewer heterotypic LCs with more lymphocytes
sequestered per cluster.
The clinical significance of FD difference of B cells in heterotypic
LCs is illustrated by the RFS plot in Fig. 6j. For CD3+ T cells in
heterotypic LCs, occupancy AUC is significant (p= 0.01) but FD
difference is not significant (p= 0.3) (Fig. 6k, l). FD difference of B
cells and T cells that are in the same heterotypic LCs differ in
significance because higher T cell density results in more squares
with 1’s and hence, a higher FD (FD ~ 1) at small length scales
(10–40 μm). As a result, the difference in FD between large
(200–600 μm) length scales (good (n= 24) FD= 1.3; poor (n= 12)
FD= 1.1; p= 0.04) and small length scales will be less for T cells
than for B cells in heterotypic LCs. Lower B cell density produces a
lower FD for small square sizes in the range of 10–40 μm (good
(n= 24) FD= 0.67; poor (n= 12) FD= 0.78; p= 0.2), resulting in a
larger difference in FD between large length scales (good (n= 24)
FD= 1.1; poor (n= 12) FD= 0.90; p= 0.1) and small length scales.
Fig. 5 Density and spatial dispersion of isolated lymphocytes and isolated CD3+ T cells within stroma are significantly higher for good
outcome tumors, but not for isolated stromal CD20+ B cells. Density of isolated (a) lymphocytes, (b) CD20+ B cells, and (c) CD3+ T cells
within stroma for good vs. poor outcome tumors. Plots of (d) occupancy AUC and (e) FD difference of isolated CD3+ T cells within stroma
showing greater spatial dispersion in good compared to poor outcome. Plots of (f) occupancy AUC and (g) FD difference showing that spatial
dispersion of isolated B cells within stroma is not significantly different between good vs. poor outcome. Patient cohorts for plots in this figure
are n= 24 for good outcome (blue) and n= 12 for poor outcome (red). For all box-and-whisker plots, the center line represents the median,
box limits represent the upper and lower quartiles, whiskers indicate maximum and minimum values within 1.5 interquartile ranges of the
upper and lower quartiles; individual points are outliers. P-values in box plots are determined by unpaired, two-tailed Student t-tests. ns: not
significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 1 × 10−4.
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Fig. 6 LCs are smaller, more numerous, and more evenly distributed in good outcome. a Sample image showing TLS. Color code: Nuclei
(DAPI, dark blue), B cells (CD20+; yellow), DC-LAMP (magenta), PNAd (green), and cancer cells (Pan-cytokeratin cells; red). b Fraction of
heterotypic LCs with more than 30% B cells is lower for good (n= 24) vs. poor outcome (n= 12) tumors. Plots showing (c) number of
heterotypic LCs per cm2 and (d) number of pure T cell LCs per cm2 are higher for good outcome. e Cluster size distribution showing
heterotypic LCs are smaller and more numerous in good outcome vs. poor outcome tumors. (Inset) Cumulative fractions of lymphocytes that
belong to heterotypic LCs of a given size (population) or smaller show that there are more small clusters in good outcome, and more large
clusters in poor outcome, as indicated by crossing of the curves at large cluster sizes. f Cluster size distribution of pure T LCs showing no
significant difference between good and poor outcome tumors (see “Methods” section for normalization of distributions). (Inset) Cumulative
fractions of T cells that belong to pure T cell LCs of a given size (population) or smaller lack distinction between good vs. poor outcome. Plots
of (g) occupancy AUC of B cells in heterotypic LCs and (h) FD difference for B cells in heterotypic LCs, indicating that B cells in heterotypic LCs
are more spatially dispersed in good outcome. i Cartoon illustrating lymphocytes in LCs that are more spread out (left panel: good outcome)
vs. more aggregated (right panel: poor outcome). Each color corresponds to a unique LC. Black points are isolated lymphocytes. j RFS plot
showing the clinical significance of FD difference of B cells in heterotypic LCs with a threshold value of 0.417 (see “Methods”). k Plot showing
occupancy AUC of CD3+ T cells in heterotypic LCs is higher in good outcome. l Plot showing FD difference for CD3+ T cells in heterotypic LCs
is not significantly different between good and poor outcome. Pure T cell LCs are more evenly distributed in good outcome: (m) occupancy
AUC and (n) FD difference of T cells in pure T cell LCs is higher in good outcome. Spatial distribution of LCs is not attributable to the spatial
distribution of stromal cells: (o) occupancy AUC and (p) FD difference of all stromal cells is not significantly different between good vs. poor
outcome. Patient cohorts for all plots in this figure are n= 24 for good outcome (blue) and n= 12 for poor outcome (red). For all box-and-
whisker plots, the center line represents the median, box limits represent the upper and lower quartiles, whiskers indicate maximum and
minimum values within 1.5 interquartile ranges of the upper and lower quartiles; individual points are outliers. P-values in box plots are
determined by unpaired, two-tailed Student t-tests. ns: not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 1 × 10−4.
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T cells in pure T cell LCs are more spatially dispersed in good
outcome
A small percentage (about 13%) of CD3+ T cells are in pure T cell
LCs. There is no significant difference in the fraction of T cells in
pure T cell LCs between good vs. poor outcome tumors (p= 0.6).
However, occupancy AUC and FD differences of pure T cell LCs
was significantly higher in good outcome (occupancy AUC: p=
3 × 10−4; FD difference: p= 3 × 10−4), indicating that these T cells
are more spatially dispersed in good outcome (Fig. 6m, n). Of note,
the p-values for occupancy AUC and FD differences in pure T cell
LCs are about two orders of magnitude more significant than for
heterotypic LCs, indicating that spatial distribution of pure T LCs
has greater clinical significance. This difference may be related to
the density of T cells being a better prognostic indicator than the
density of B cells, since the cell density influences occupancy
and FD.
Spatial distribution of LCs is not attributable to spatial
distribution of stromal cells
Since a large fraction of lymphocytes in LCs are located within the
stroma (good (n= 24) 0.80; poor (n= 12): 0.91; p= 0.05), we
investigated whether the spatial distribution of LCs was dictated
by exclusion from cancer cell islands. So we computed the
occupancy and FD difference of stromal cells which, by definition,
are not within cancer cell islands. Occupancy AUC of stromal cells
is not significantly different between good vs. poor outcome
tumors (p= 0.9) (Fig. 6o). Similarly, FD difference is not
significantly different for poor outcome vs. good outcome tumors
(p= 0.3) (Fig. 6p), indicating that stromal cells are similarly
distributed in good and poor outcomes. This also indicates that
the spatial distribution of lymphocytes that are within LCs, as well
as the spatial distribution of B cells overall, is not due to the spatial
structure of the stroma in which they reside.
Heterotypic and pure T cell LCs are closer to cancer cell islands
in good outcome tumors
Pure T cell LCs tend to be closer to cancer cell islands than
heterotypic LCs, regardless of outcome (Fig. 7a). Distance between
each LC and its nearest cancer cell island is defined as the shortest
distance between a lymphocyte within the LC and a cell within the
nearest cancer island. The mean of such distances is significantly
shorter in good outcome compared to poor outcome tumors for
both heterotypic and pure T cell LCs (heterotypic LCs: good (n=
24): 91 μm; poor (n= 12): 200 μm; p= 0.002; pure T cell LCs: good
(n= 24): 73 μm; poor (n= 12): 180 μm; p= 8 × 10−5) (Fig. 7b, c).
The clinical significance of the mean distance between LCs and
cancer islands is shown in RFS plots in Fig. 7d, e. Furthermore, for
good outcome, the size of heterotypic LCs is correlated with their
distance from cancer cell islands: smaller LCs have a greater
probability of being closer to cancer cell islands (n= 24, Pearson’s
r= 0.42, p= 0.04) (Fig. 7f). This correlation is absent in poor
outcomes and for pure T LCs.
Table 2. Relative average proportions of B and T cells in heterotypic
LCs, pure T LCs, and TLS.







Heterotypic 0.27 0.38 0.04
Th cells Heterotypic 0.42 0.38 0.3
CD8+ T cells Heterotypic 0.26 0.19 0.07
Tregs Heterotypic 0.055 0.050 0.7
Th cells Pure T 0.53 0.54 0.8
CD8+ T cells Pure T 0.35 0.31 0.3
Tregs Pure T 0.12 0.15 0.4
CD20+
B cells
TLS 0.51 0.62 0.3
Th cells TLS 0.30 0.21 0.2
CD8+ T cells TLS 0.15 0.15 1.0
Tregs TLS 0.034 0.023 0.6
In a good outcome, the proportion of T cells is higher while the proportion
of B cells is lower. Only lymphocytes are used in computing relative
proportions.
Fig. 7 LCs are closer to cancer cell islands in good outcome. a Distribution of distances from LCs to cancer islands shows pure T LCs tend to
be closer to cancer islands than heterotypic LCs. Distribution of mean distances between an LC and its nearest cancer cell island shows that (b)
heterotypic and (c) pure T cell LCs are closer on average to cancer cell islands in good outcome. RFS plots showing the clinical significance of
mean distance between (d) heterotypic or (e) pure T cell LCs and the nearest cancer cell island. (See “Methods” for how RFS thresholds were
chosen.) f Smaller heterotypic LCs tend to be closer to cancer cell islands in the good outcome as shown in the scatter plot of the average size
(number of cells) of LCs vs. the shortest distance between a heterotypic LC and the nearest cancer cell island. Each point represents a patient.
Blue is for good outcome and red is for poor outcome. Pearson’s r= 0.42, p= 0.04 for good outcome indicates significant correlation while r=
0.09, p= 0.6 for poor outcome. Patient cohorts for all panels in this figure are n= 24 for good outcome (blue) and n= 12 for poor outcome
(red). Computation of mean distance used in plots: The mean distance is found for each patient and then the average over all patients is
calculated to produce the mean distances.
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DISCUSSION
Recent studies highlight the clinical significance of B cells in
certain human tumors, specifically melanoma and sarcoma8–10.
However, their role in breast tumors remained unclear. Our results
indicate that while the overall density of B cells in TNBC tumors is
not clinically significant, B and T cell density within cancer cell
islands is significantly higher in good outcome tumors. One
speculative reason for TIL infiltration into cancer cell islands is that
the cancer islands arise from tumor self-seeding by circulating
cancer cells that bring associated lymphocytes with them27,
(Norton, L., 2019, Private communication). Another possibility is
that cytokines and chemokines specifically recruit lymphocytes to
cancer islands. In addition, the higher density of B cells infiltrating
cancer cell islands in good outcome may be due to a greater
diversity of B cell receptors and recognition of cognate tumor
antigens. Helmink et al.9 found an increased diversity of B cell
receptors in responders to immunotherapy compared to non-
responders.
Our observation that the density of B and T cells within cancer
cell islands is associated with clinical outcome is consistent with
previous TNBC studies of neoadjuvant therapy that found
densities of both stromal and intraepithelial TILs predictive of
pathological response28,29. Interestingly, for the luminal subtype of
breast cancer, only intraepithelial TILs, not stromal TILs, were
indicative of pathological response29. However, the established
guidelines for evaluating TILs in breast cancer discourage using
intraepithelial TILs for prognostication because, compared to
stromal TILs, their paucity makes them rarer and harder to
detect30.
Beyond cell density, B and T cells are more spatially dispersed,
within both cancer cell islands and stroma, in good outcome.
Consistent with other studies, the majority of TILs are found in
stroma. Importantly, most TILs form LCs that are either heterotypic
(mixed T and B cells) or pure T cells. LCs comprised of only
CD20+ B cells were rare. Both types of LCs are more abundant
and more spatially dispersed in good outcome vs. poor outcome.
In good outcome tumors, heterotypic LCs are smaller and more
numerous compared to poor outcome. These attributes reflect
the spatial distribution of LC constituent B and T cells and cannot
be attributed to differences in the spatial distribution of cells
constituting the stroma where most lymphocytes are found.
Heterotypic LCs are closer to cancer islands in good outcome, with
LC size (population) decreasing as they get closer to cancer
islands. Although segregation of B and T cells is similar in
heterotypic LCs and TLS, the number and density of lymphocytes
in the majority of heterotypic LCs are too small for these
heterotypic LCs to qualify as TLS. Given that TLS with high
lymphocyte density are linked to good prognosis, it is somewhat
ironic that good outcome is associated with isolated B cells within
cancer cell islands and with spatially dispersed B cells, both of
which connote low local concentrations of B cells and are the
antithesis of high B cell density germinal centers found in
mature TLS.
The biological role of B cells within tumors remains unclear.
CD20+ B cells are not antibody-producing plasma cells since
plasma cells do not express CD20. It is possible that CD20+ B cells
act as antigen-presenting cells (APCs) within tumors. Spatial
dispersion of CD20+ B cells in good outcome is consistent with
their ability to forage over a large region, including in cancer
islands, to gather antigens that can be presented to Th cells in
heterotypic LCs and TLS. Th cells comprise a substantial fraction of
the lymphocytes in TLS and LCs. If CD20+ B cells function as APCs,
this would be consistent with the paucity of LCs consisting purely
of B cells. APC function may also explain why the density of B cells
is not correlated with clinical outcome: a single B cell can activate
many Th cells if it can spatially disperse.
The source of clinically significant differences between good
and poor outcome tumors in the spatial distribution of CD20+ B
and CD3+ T cells is not clear. This does not appear to be due to
differences in the physical topography of the stroma as we did not
find clinically significant differences in the spatial distribution of
stroma. Furthermore, immunohistochemical staining of collagen I
did not show differences in the spatial distribution of collagen I
between good and poor outcomes (data not shown). Spatially
aggregated lymphocytes in poor outcome may be associated with
immunoediting, resulting in immune-evasive cancer cell clones31.
Less spatial dispersion and larger LCs suggest a lack of motility,
e.g., in overcoming physical barriers in the stroma such as collagen
fibers, due to a lack of chemokine signaling and cognate antigens,
or a lack of metabolites due to poorly organized leaky vasculature
that produces hypoxic regions, or metabolic insufficiency from
dysfunctional depolarized mitochondria that have been asso-
ciated with exhausted CD8+ TILs32. It has been suggested that
cells are more motile if they are elongated rather than compact
and round33–35. Future studies should look for correlations
between lymphocyte clustering and cell shape, e.g., the aspect
ratio or the ratio of the cell perimeter to the square root of the
area of a cell34,35. Another finding from this study is that the
spatial distribution of TILs is fractal. We speculate that this fractal
pattern may arise from branching trajectories that B and T cells
follow as they avoid obstacles and follow along blood vessels and
collagen fibers36,37.
Our techniques minimize the noise arising from sparseness of
discrete points that correspond to cell locations because they
divide the tissue area into squares and ask binary questions that
do not depend on the exact location and number of cells in a
square. Thus, they effectively average over the larger region of a
square. Similarly, density-based clustering, used to identify LCs,
depends on the local density of several cells and is basically a form
of averaging.
Previous efforts to quantify the spatial heterogeneity of the TME
include measuring the spatial co-localization of tumor and
immune cells38,39, locating immune cell clusters or “hotspots”40,41,
determining the amount of infiltration of lymphocytes into a
tumor42, and using Shannon entropy to quantify the cellular
diversity43. In addition, FDs44 have been used to characterize the
irregular morphology of tumors18–20 and tumor-related struc-
tures21–24, but not the spatial distribution of immune cells. Spatial
heterogeneity connotes local variations in density; this implies a
certain size (or length scale) of a region in which density is
calculated. All these approaches produce measures of the spatial
distribution at a single length scale. The statistical techniques that
we have developed move beyond this limitation to quantify how
the spatial distribution varies with length scale and then use this
to determine whether the cells are clustered or spatially dispersed.
On a more general level, these approaches are flexible and
applicable to a broad spectrum of problems that go beyond the
spatial distribution of cells or discrete entities. More complex
binary questions can be employed to explore the proximity of
cells and structures indicative of possible function, e.g., regarding
co-localization of at least one T cell and a dendritic cell
(suggesting antigen presentation by the dendritic cell) or
proximity of at least one B cell and one T cell near a blood vessel
(suggesting lymphocyte extravasation).
While our results are suggestive, they should be interpreted
with caution due to some limitations. The first is the small patient
sample size; follow-up studies should involve a much larger cohort
of patients. Second, the TNBC patients were somewhat diverse in
their disease characteristics and were not uniformly treated after
tumor resection, though none had treatment before surgery.
Nevertheless, our results indicate the importance of the spatial
distribution of B cells within human TNBC tumors with regard to
clinical outcomes. These findings raise new questions about the
biology and clinical impact of TILs. Of particular interest is the
J.C. Wortman et al.
10
npj Breast Cancer (2021)    84 Published in partnership with the Breast Cancer Research Foundation
discordant significance of B cell density vs. spatial distribution on
the outcome of TNBC. The role of B cells within tumors is
understudied and remains unclear, partially due to prior reports
that their density within tumors is of no significance. Our finding of
the strong correlation of B cell spatial distribution with clinical
outcome in TNBC revives their significance in cancer, and opens up
new questions on their functional role in preventing recurrence.
METHODS
Breast cancer tissue sample preparation and analysis
Tissue preparation, multi-color antibody staining, and image analysis.
Specimens were identified through an IRB-approved protocol via the City
of Hope (COH) Biospecimen Repository which is funded in part by the
National Cancer Institute. The IRB granted a waiver of informed consent
from all human participants because de-identified tissue samples were
obtained from the CoH Biospecimen Repository. Samples from patients
diagnosed with TNBC and treated at COH from 1 January 1994 to 4 March
2015 were retrieved. Eligible patients had the following features: stage I-III
breast cancer; at least one tumor biospecimen was available from the
initial surgical resection or biopsy; clinical outcome data were available for
identification of relapse-free survival; no prior treatment at the time of
surgical biopsy. Archived FFPE tumor tissues were sectioned (i.e., 3–5 μm
per slide) and on the same slide, multi-color immunostaining was
performed including anti-pan cytokeratin (1:2850, Cat. # M351501-2, AE1/
AE3, Dako), anti-CD8 (1:250, Cat. # CRM 311C, SP16, Biocare), anti-CD3
(1:1000, Cat. # A045201-2, Polyclonal, Dako), anti-FOXP3 (Ready-To-Use,
Cat. # API 3164 AA, 236A/E7, Biocare) and anti-CD20 (1:450, Cat. #
M075501-2, L26, Dako). Samples were further counterstained with DAPI to
visualize the nuclei of all cells. Prior to imaging, the tissue sections were
coverslipped with ProLong® Gold Antifade mounting media (Cat. #
P36930, Life Technologies). All the images were acquired using the Vectra
3.0 Automated Quantitative Pathology Imaging System (Akoya Bios-
ciences) and commercially available software packages (inForm, Akoya
Biosciences) were used to identify each cell, define its type (cancer or
specific immune), and assign it Cartesian coordinates. Using an automated
tissue segmenter algorithm built in inForm®, we further divided the
images into areas of cancer islands and stroma based on anti-pan
cytokeratin antibody staining.
Spatial distribution analysis of TILs. Using the data spreadsheets with
every cell phenotyped and given a set of Cartesian coordinates, we tiled
each image with a grid of identical squares. We omitted squares that had
no cells, since they lay outside the tissue. However, we included squares
that were within the tissue but contained no cells of interest. The length L
of one side of a square varies from 10 to 600 μm. A square was assigned 1
or 0 according to the answer to a binary question. For comparison we
calculated the occupancy FD of a uniform random (Poisson) distribution of
points. We processed the data using in-house custom-developed software
(RStudio) and the R packages “spatstat” for point patterns, “dbscan” for
cluster analysis, and “EBImage” for raster images45,46.
Statistical methods
Occupancy15,16. An image is overlaid with a grid of squares (Fig. 2a); each
square has an area of L2. A ‘0’ or ‘1’ is assigned to each square according to
the answer to a binary (yes-no) question, e.g., “Is there at least one B cell in
the square?” (Fig. 2a inset). The occupancy is the fraction of squares with
1’s, i.e., it is an estimate of the probability that a square will have a 1. To
characterize the spatial distribution at different length scales, the size of
the squares in the grid is varied to produce the occupancy as a function of
L, the length of one side of a square. The occupancy depends to some
extent on the average cell density for binary questions such as “Is there at
least one CD20+ B cell in the square?” because a higher average cell
density corresponds to a higher probability that a square is assigned a ‘1’.
Fractal dimension (FD)15,16. FDs can be used to characterize the number
of grid squares with 1’s and hence, the spatial distribution of cells. While
there are a number of different ways to define the FD, we chose a variation
of the box-counting method17. As a way of introducing FD, note that the
number of tiles, each with area L2, needed to cover a floor is proportional
to 1/L2, where the exponent “2” is due to the floor being two-dimensional.
Now consider a 2D image covered with a grid of squares (each with area
L2) as described above, with 1’s and 0’s corresponding to the answers to a
binary question. The number n(L) of squares with ‘1’ will be proportional to
(1/Lδ) where the exponent δ is one type of FD and is ≤217. If the system is
self-similar and fractal over a range of length scales L, n(L) will follow a
power law: n(L)= A/(Lδ), and the exponent δ will remain constant as L
varies. The constant of proportionality, A, depends on the size of the tissue
that dictates the number of boxes covering the tissue. To avoid this, we
define the FD as follows. In a plot of log [n(L)] versus log[A/L], where A is a
constant, the FD is the slope s of a line fit through the points using linear
regression with a least-squares fit, i.e., s(L)=−d[log n(L)]/d[log L]. (Note
that unlike the more common definition of the box-counting FD, the limit
L→0 is not taken because of our interest in the distribution of individual
cells at different length scales.) The FD over a range of values of L is
determined for each patient and then averaged over all patients with a
given clinical outcome.
Occupancy and FDs of lymphocytes in cancer islands. In the calculations of
the occupancy and FD with a grid of squares covering the tissue, squares
with at least one CD20+ B cell (or T cell) in a cancer cell island were
assigned a ‘1’, while squares covering stroma had zeros. The fraction of
squares with 1’s, i.e., the occupancy, was the number of squares with 1’s
divided by the total number of squares covering the image (including the
stroma). This can easily be generalized to calculating the occupancy and
FD of lymphocytes in the stroma or in the whole tissue.
Normalization of the distribution of cluster sizes. In Fig. 6e, f, the quantity
on the y-axis is Po,i(s)/No,i where s is the number of lymphocytes in an LC,
No,i is the total number of lymphocytes in LCs of type i (i= pure T LCs or
heterotypic LCs) and outcome o (o= good or poor), and Po,i(s) is the







0ð Þ  s0 ¼ 1 (1)
since the sum over s’ of the fraction of lymphocytes in a cluster of size s’
must equal unity. Blue line is for good outcome and red line is for poor
outcome. Insets: Cumulative fraction of lymphocytes that belong to LCs of
size s or smaller versus s. The x-axis is on a logarithmic scale. The
cumulative fraction is given by the expression





0ð Þ  s0 (2)
Plots
Throughout the paper, the threshold for RFS plots was systematically
chosen so that two thirds of the patients are in the upper curve and one
third are in the lower curve. These fractions correspond to the proportions
of good and poor outcome patients, respectively.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data generated and analysed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.1457573447. All data are contained
in the R Data file ‘PatientPointPatterns.rds’, which is openly available with the data
record. The file contains a list of 36 marked point patterns in ppp format, usable by
the R package “spatstat”. Each pattern corresponds to a single patient. Relevant
marks include “Tissue.Category” (marks points as belonging to cancer islands or
stroma) and “Phenotype” (marks points as cancer, stromal, or immune cells). X and Y
coordinates have units of μm.
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